Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAVO: Beta Blocker Dialyzability on Cardiovascular Outcomes
NCT05931276Phase 3Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of metoprolol, carvedilol in end-stage kidney disease (ESKD), sponsored by VA Office of Research & Development. Started May 2024; status: recruiting.
02
Drugs
metoprololcarvedilol
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NCT05931276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05931276.